Juvenile nasopharyngeal angiofibroma

Juvenile nasopharyngeal angiofibroma (JNA), also called juvenile nasal angiofibroma or simply nasopharyngeal angiofibroma, is a rare, non-cancerous (benign) tumor that grows in the back of the nasal cavity where the nose meets the throat (an area called the nasopharynx). Despite being benign, this tumor can be locally aggressive, meaning it tends to grow into surrounding structures like the sinuses, eye sockets, and even the base of the skull. It occurs almost exclusively in adolescent males, typically between the ages of 10 and 25. The most common symptoms include one-sided nasal blockage (stuffiness) and repeated nosebleeds that can sometimes be severe. As the tumor grows, it may cause facial swelling, headaches, difficulty breathing through the nose, reduced sense of smell, and changes in vision if it presses on nearby structures. Some patients may also experience hearing changes if the tumor blocks the opening of the ear canal in the throat. The primary treatment for JNA is surgical removal. Before surgery, doctors often perform a procedure called embolization, which reduces blood flow to the tumor to minimize bleeding during the operation. Advances in endoscopic surgery (using a camera through the nose) have greatly improved outcomes, allowing many tumors to be removed without external incisions. Radiation therapy may be considered for tumors that cannot be fully removed surgically or that recur. Hormonal therapy has been explored but is not standard. With appropriate treatment, the outlook is generally good, though recurrence can happen in some cases and requires ongoing monitoring.

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Juvenile

Begins in the teen years

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

Bring these to your next appointment

• Q1.What stage is the tumor, and how far has it spread into surrounding structures?,Is endoscopic surgery an option, or will a more extensive open surgery be needed?,Will embolization be performed before surgery, and what are the risks?,What is the chance of the tumor coming back after surgery, and how will we monitor for recurrence?,Are there any risks to vision, hearing, or facial growth from the surgery?,How long will recovery take, and when can normal activities like school and sports resume?,If the tumor recurs, what are the next treatment options, including radiation therapy?

Common questions about Juvenile nasopharyngeal angiofibroma

Related conditions

Other rare diseases commonly researched alongside Juvenile nasopharyngeal angiofibroma.

• Nasopharyngeal carcinoma→